Stock comparison
Ascendis Pharma A/S
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ASND
Ascendis Pharma A/S
Market cap
$15.26B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ASND | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 24F | 79B | HALO |
| Benjamin Graham | 56D | 83A | HALO |
| Philip Fisher | 44D | 65B | HALO |
| Peter Lynch | 70B | 53D | ASND |
| Joel Greenblatt | 13F | 40D | HALO |
| Charlie Munger | 46D | 80C | HALO |
| Terry Smith | 32F | 84A | HALO |
Side-by-side metrics
| Metric | ASND | HALO |
|---|---|---|
| Market cap | $15.26B | $8.1B |
| P/E (TTM) | 24.7x | 24.0x |
| EV/EBIT | - | 10.2x |
| ROIC (TTM) | 1.51% | 23.65% |
| Gross margin | 88.17% | 81.24% |
| Net margin | 58.4% | 23.13% |
| Revenue CAGR 5y | 2.07% | 33.23% |
| EPS CAGR 5y | 4.56% | -1.98% |
| Debt / Equity | 1.8x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ASND leads on
- EPS CAGR 5y4.56%vs -1.98%+143%
- EV/EBIT-vs 10.2x+110%
- Revenue CAGR 5y2.07%vs 33.23%+84%
- Net margin58.4%vs 23.13%+60%
HALO leads on
- ROIC (TTM)23.65%vs 1.51%+94%
- Debt / Equity1.0xvs 1.8x+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.